Australia markets closed

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7800+0.1300 (+7.88%)
At close: 04:00PM EDT
1.8600 +0.08 (+4.49%)
After hours: 07:59PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
345
380,786
22,230
0
0
-
Cost of revenue
136,564
25,441
2,993
0
-
-
Gross profit
261,437
355,345
19,237
0
-
-
Operating expenses
Research development
84,031
128,187
93,450
44,040
24,594
-
Selling general and administrative
101,205
188,356
127,128
38,933
15,061
-
Total operating expenses
185,236
316,543
220,578
82,688
39,005
-
Operating income or loss
-185,063
38,802
-201,341
-82,688
-39,005
-
Interest expense
-
-
-
0
2,288
1,276
Total other income/expenses net
79
-660
-551
-5,279
-1,001
-
Income before tax
-183,820
54,297
-197,601
-87,931
-42,280
-
Income tax expense
5,438
5,026
774
0
-
-
Income from continuing operations
-184,015
49,271
-198,375
-87,931
-42,280
-
Net income
-184,015
49,271
-198,375
-87,931
-42,280
-
Net income available to common shareholders
-184,015
49,271
-198,375
-87,931
-42,280
-
Basic EPS
0.04
0.73
-3.39
-1.59
-0.92
-
Diluted EPS
0.01
0.70
-3.39
-1.59
-0.92
-
Basic average shares
66,716
67,234
58,496
55,216
45,951
-
Diluted average shares
68,981
69,991
58,496
55,216
45,951
-